Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATSN-101 in GUCY2D-LCA
NCT03920007Phase 2Active, not recruiting
- Sponsor
- Atsena Therapeutics
- Start
- Oct 2019
- Primary completion
- May 2023
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of ATSN-101 in Leber congenital amaurosis (LCA), sponsored by Atsena Therapeutics. Started Oct 2019; status: active, not recruiting.
02
Drugs
ATSN-101
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT03920007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920007.